THE SINGLE BEST STRATEGY TO USE FOR SEVITERONEL

-mutated tumors. Nonetheless, only a fraction of those clients responds to immune checkpoint or PARP inhibitors and also individuals that do respond typically establish resistance and relapse.Mechanistically, we report differential binding of AR to focus on genes during the presence of enzalutamide and seviteronel, suggesting different mechanisms o